This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Also in 2008, DiCaprio starred in Body of Lies, a spy film based on the novel of the same name. He played one of three agents battling a terrorist organization in the Middle East. Considering the film to be a throwback to political features of the 1970s like The Parallax View (1974) and Three Days of the Condor (1975), DiCaprio dyed his hair brown and wore brown contacts for the role. The film received mixed reviews from critics, and grossed $118 million against a budget of $67.5 million. Later in 2008, DiCaprio collaborated with Kate Winslet for the drama Revolutionary Road, directed by her then-husband Sam Mendes. As both actors had been reluctant to make romantic films similar to Titanic, it was Winslet who suggested that they both work with her on a film adaptation of the 1961 eponymous novel by Richard Yates. She found that the script, by Justin Haythe, had little in common with the 1997 blockbuster. Playing a couple in a failing marriage in the 1950s, DiCaprio and Winslet spent some time together in preparation, and DiCaprio felt claustrophobic on the small set they used. He saw his character as "unheroic", "slightly cowardly" and someone "willing to be just a product of his environment". Peter Travers liked DiCaprio's pairing with Winslet and his multi-layered portrayal of an overwhelmed character, and Marshall Sella of GQ called it the "most mature and memorable performance of his lifetime". DiCaprio earned his seventh Golden Globes nomination for the film. Revolutionary Road grossed $75.9 million against its budget of $35 million.
== Prognosis == Most skin grafts are successful, but in some cases grafts do not heal well and may require repeat grafting. The graft should also be monitored for good circulation. Recovery time from skin grafting can be long. Graft recipients wear compression garments for several months and are at risk for depression and anxiety consequent to long-term pain and loss of function.
Long term preservation of fish is accomplished in a variety of ways. The oldest and still most widely used techniques are drying and salting. Desiccation (complete drying) is commonly used to preserve fish such as cod. Partial drying and salting are popular for the preservation of fish like herring and mackerel. Fish such as salmon, tuna, and herring are cooked and canned. Most fish are filleted before canning, but some small fish (e.g. sardines) are only decapitated and gutted before canning.
Sources: en.wikipedia.org
== Function == GnRH is secreted in the hypophysial portal bloodstream at the median eminence. The portal blood carries the GnRH to the pituitary gland, which contains the gonadotrope cells, where GnRH activates its own receptor, gonadotropin-releasing hormone receptor (GnRHR), a seven-transmembrane G-protein-coupled receptor that stimulates the beta isoform of Phosphoinositide phospholipase C, which goes on to mobilize calcium and protein kinase C. This results in the activation of proteins involved in the synthesis and secretion of the gonadotropins LH and FSH. GnRH is degraded by proteolysis within a few minutes. GnRH activity is elevating during fetal life, drops briefly following birth due to the effect of placental hormones, then becomes elevated again for the first one to six months of life in a period known as minipuberty, during which time gonadotropins and sex steroids contribute to the development of sexual organs. GnRH is very low during childhood, and is reactivated at puberty during adolescence. During the reproductive years, pulse activity is critical for successful reproductive function as controlled by feedback loops. However, once a pregnancy is established, GnRH activity is not required. Pulsatile activity can be disrupted by hypothalamic-pituitary disease, either dysfunction (i.e., hypothalamic suppression) or organic lesions (trauma, tumor). Elevated prolactin levels decrease GnRH activity. In contrast, hyperinsulinemia increases pulse activity leading to disorderly LH and FSH activity, as seen in polyendocrine metabolic ovarian syndrome (PMOS).
Computational techniques complement the chemoproteomic toolkit as parallel lines of evidence supporting potential drug-target pairs, and are used to generate structural models that inform lead optimization. Several targets of high profile drugs have been identified using chemoproteomics, and the continued improvement of mass spectrometer sensitivity and chemical probe technology indicates that chemoproteomics will play a large role in future drug discovery.
These physiological changes in the decomposers also alter the local environment in a way that allows certain minerals to be deposited, while others remain in solution. Generally, however, a fossilizing egg's shell keeps the same calcite it had in life, which allows scientists to study its original structure millions of years after the developing dinosaur hatched or died. However, eggs can also sometimes be altered after burial. This process is called diagenesis. One form of diagenesis is a microscopic cross-hatched pattern imposed on the eggshell by the pressure of being buried deeply. If the pressure gets severe enough, sometimes the eggshell's internal microscopic structure can be completely destroyed. Diagenesis can also happen chemically in addition to physically. The chemical conditions of a decomposing egg can make it easy for silica to be incorporated into eggshell and damage its structure. When iron-bearing substances alter eggshell it can be obvious because compounds like hematite, pyrite, and iron sulfide can turn the shell blackish or rusty colors.
Sources: en.wikipedia.org
=== Other risks === Smoking is a risk factor for MS. Similarly, air pollution seems to increase MS risk, as well as the risk of relapses. Organic solvent exposure and night shift work are linked to increased risk of MS, but are not as established as other risk factors. Vaccinations were studied as causal factors; most studies, though, show no association. The risk of developing MS is also weakly associated with obesity, and the presence of certain bacteria such as Akkermansia muciniphila in the intestines.
=== mzPeak === Due to the increasing size of mass spectrometry raw-data files, the XML-backed mzML specification does not perform well enough with compressed data. The mzPeak format solves that by saving multiple files in an uncompressed zip file, with the raw data stored in parquet files for fast random access. The structure of the format is heavily inspired by mzML. Its specification is under development, as of September 2026, by HUPO-PSI and interested parties.
In Weeds episode "Lude Awakening" the character Celia Hodes, portrayed by actress Elizabeth Perkins, states, "I hold in my hand the last Quaalude on earth. See you around, girls." Season 18 of Law & Order: Special Victims Unit addresses Quaalude administration as a date rape drug in episode 9, "Decline and Fall", which aired January 18, 2017. In the first season of True Detective, Rust Cohle's use of Quaaludes is briefly mentioned in several episodes. It is also used by Patrick Melrose in Edward St Aubyn's 1992 novel Bad News. In the 2024 film Maria, Maria Callas, played by Angelina Jolie, stuffs Mandrax into the pockets of her coats and bags so that she'll be able to escape detection by her butler/guardian Ferruccio (Pierfrancesco Favino). The 2000 novel House of Leaves by Mark Z. Danielewski features the supporting character named Lude, referencing Quaaludes. In the 2026 song, Burning Bridges by rapper Drake, he references the substance with the lyric "I'm off a Quay, it make my body tingle”.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.